KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $190.6 million.

  • Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) rose 0.86% to $192.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $192.0 million, marking a year-over-year increase of 0.86%. This contributed to the annual value of $190.6 million for FY2024, which is 1.18% up from last year.
  • As of FY2024, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) stood at $190.6 million, which was up 1.18% from $188.4 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) registered a high of $190.6 million during FY2024, and its lowest value of $181.5 million during FY2020.
  • For the 3-year period, Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) averaged around $188.3 million, with its median value being $188.4 million (2023).
  • Data for Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) shows a peak YoY increased of 1.36% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Shares Outstanding (Weighted Average) stood at $181.5 million in 2020, then rose by 1.14% to $183.6 million in 2021, then climbed by 1.23% to $185.8 million in 2022, then climbed by 1.36% to $188.4 million in 2023, then climbed by 1.18% to $190.6 million in 2024.